~~<i id='B8F43BE82E'><strike id='B8F43BE82E'><tt id='B8F43BE82E'><pre id='B8F43BE82E'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

explore

author：focus 2025-09-07 14:10:42 - browse：8628

Sanofi will license a new CRISPR enzyme from the startup Scribe Therapeutics in a bid to be the first to develop a safer, simpler, and more scalable cure for sickle cell disease.

The French drugmaker will pay Scribe $40 million upfront and promise another $1.2 billion in potential milestones to license a DNA-cutting enzyme called CasX for use in a potential single-infusion treatment for the serious blood disorder — what’s known as in vivo therapy.CasX was discovered in CRISPR pioneer Jennifer Doudna’s lab, which subsequently spun out Scribe.

Scribe was planning to announce the news Tuesday, but it was published early Monday by GEN.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： How to increase colonoscopy rates? Looks like an AI can help

Wikipedia

focus

Wikipedia

entertainment

PauloAmorim/VWPicsviaAPImagesLONDON—EuropeanregulatorsonFridayreiteratedtheirviewthatanALStreatmentf

WSS

Ionis drug prevents swelling attacks due to hereditary angioedema

Better Therapeutics data on benefit with GLP

STAT Readout: Today's biotech news includes Sana and Amylyx

How to increase colonoscopy rates? Looks like an AI can help

A fraught question for the kids of Alzheimer’s: Is it coming for us?

Massive project maps cells in human brain in unprecedented detail

focus

explore

Wikipedia

Heart attack and stroke risk calculators need revising

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

How one medical school became remarkably diverse

What the Wegovy shortage looks like for doctors — and for patients

Cancer drug shortages should be causing more outrage

Ultragenyx gene therapy for rare liver ailment succeeds in late

How to save PrEP access — and even expand it

Eight reasons why you should get an updated Covid vaccine

Wildfire smoke exposes gaps in outdoor worker protections

Innovation in antibiotics is ailing. 'Brain drain' may kill it

focus

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Shifting the focus from loneliness to social health

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

There’s no way to know how good AI health technologies are

What the Wegovy shortage looks like for doctors — and for patients

A revolution in caring for preterm infants

Wikipedia

Wikipedia

entertainment

entertainment